Stockscreener 앱 받기
5.02
2.24%
-0.12
전일 마감가:
$5.14
열려 있는:
$5.05
하루 거래량:
192.80K
Relative Volume:
0.17
시가총액:
$278.51M
수익:
$1.02B
순이익/손실:
$-757.20M
주가수익비율:
-0.3401
EPS:
-14.76
순현금흐름:
$-257.90M
1주 성능:
-7.80%
1개월 성능:
+11.17%
6개월 성능:
-43.92%
1년 성능:
+29.18%
1일 변동 폭
$4.94
$5.115
1주일 범위
$4.90
$5.55
52주 변동 폭
$3.84
$15.10
Emergent Biosolutions Inc Stock (EBS) Company Profile
명칭
Emergent Biosolutions Inc
전화
240-631-3200
주소
300 PROFESSIONAL DR, GAITHERSBURG, MD
EBS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
EBS
Emergent Biosolutions Inc
|
5.03 | 278.51M | 1.02B | -757.20M | -257.90M | -14.76 |
|
ZTS
Zoetis Inc
|
157.24 | 68.50B | 9.26B | 2.49B | 2.30B | 5.47 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.35 | 47.71B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
HLN
Haleon Plc Adr
|
10.59 | 46.12B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.41 | 18.55B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
295.51 | 13.40B | 2.76B | 1.11B | 898.10M | 22.77 |
Emergent Biosolutions Inc Stock (EBS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-30 | 개시 | H.C. Wainwright | Buy |
| 2024-08-22 | 개시 | Rodman & Renshaw | Buy |
| 2024-03-07 | 업그레이드 | The Benchmark Company | Hold → Buy |
| 2023-11-20 | 재개 | JP Morgan | Underweight |
| 2023-08-29 | 다운그레이드 | The Benchmark Company | Buy → Hold |
| 2023-04-10 | 업그레이드 | The Benchmark Company | Hold → Buy |
| 2023-03-17 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2022-11-10 | 다운그레이드 | The Benchmark Company | Buy → Hold |
| 2022-04-29 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2022-01-20 | 업그레이드 | The Benchmark Company | Hold → Buy |
| 2021-11-08 | 다운그레이드 | The Benchmark Company | Buy → Hold |
| 2021-05-05 | 다운그레이드 | Argus | Buy → Hold |
| 2021-04-07 | 개시 | The Benchmark Company | Buy |
| 2021-02-24 | 업그레이드 | Chardan Capital Markets | Neutral → Buy |
| 2021-02-19 | 다운그레이드 | Chardan Capital Markets | Buy → Neutral |
| 2021-01-08 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2020-09-14 | 재개 | JP Morgan | Neutral |
| 2020-07-31 | 재확인 | Chardan Capital Markets | Buy |
| 2019-09-12 | 개시 | Guggenheim | Buy |
| 2019-09-04 | 업그레이드 | Wells Fargo | Market Perform → Outperform |
| 2018-11-02 | 업그레이드 | Goldman | Neutral → Buy |
| 2018-08-03 | 재확인 | Chardan Capital Markets | Buy |
| 2018-06-13 | 개시 | Argus | Buy |
| 2018-04-25 | 다운그레이드 | Wells Fargo | Outperform → Market Perform |
| 2018-01-24 | 개시 | Goldman | Neutral |
| 2018-01-16 | 재확인 | Chardan Capital Markets | Buy |
| 2016-06-28 | 재확인 | Singular Research | Buy |
| 2016-04-15 | 개시 | Chardan Capital Markets | Buy |
| 2016-03-28 | 개시 | Singular Research | Buy |
| 2016-02-19 | 개시 | Wells Fargo | Outperform |
| 2014-05-15 | 개시 | Summer Street Research | Buy |
| 2011-05-31 | 재확인 | WBB Securities | Strong Buy |
| 2011-01-10 | 재확인 | Wedbush | Outperform |
| 2010-11-05 | 재확인 | Wedbush | Outperform |
| 2010-08-18 | 업그레이드 | WBB Securities | Buy → Strong Buy |
| 2010-08-06 | 재확인 | Caris & Company | Buy |
모두보기
Emergent Biosolutions Inc 주식(EBS)의 최신 뉴스
Naloxone Market Rises with Government Initiatives to Combat Opioid Overdose | Emergent BioSolutions, Hikma, Teva - openPR.com
Emergent to supply Narcan nasal spray in Ontario (EBS:NYSE) - Seeking Alpha
Emergent BioSolutions Gets $65M Deal for Ontario Naloxone Program - MarketWatch
Emergent BioSolutions (EBS) Secures $65M Deal with Ontario for N - GuruFocus
Emergent BioSolutions Reinforces Commitment to Opioid Emergency - GuruFocus
Emergent BioSolutions Reinforces Commitment to Opioid Emergency Preparedness Efforts in Canada Through Multi-Year Contract with Ontario Ministry of Health - The Manila Times
Emergent BioSolutions Lands Major $65M Deal: Ontario Chooses NARCAN to Fight Opioid Crisis - Stock Titan
Press Release Distribution & PR Platform - ACCESS Newswire
Emergent BioSolutions to Report First Quarter 2025 Financial Results on May 7, 2025 - The Manila Times
Emergent BioSolutions Inc. to Host Conference Call on Q1 2025 Financial Results - Nasdaq
Save The Date: Emergent BioSolutions Q1 2025 Earnings Conference Call Coming May 7 - Stock Titan
Lobbying Update: $920,000 of EMERGENT BIOSOLUTIONS INC lobbying was just disclosed - Nasdaq
Emergent BioSolutions ($EBS) Is Paying a $40M Settlement to Investors — Here’s How to Get Your Share - TradingView
Institutional investors in Emergent BioSolutions Inc. (NYSE:EBS) see US$31m decrease in market cap last week, although long-term gains have benefitted them. - simplywall.st
Emergent BioSolutions launches stock repurchase program - MSN
Mile Marker Continues New Business Success With Growth-Oriented Brands - Yahoo Finance
ROSEN, A TOP RANKED LAW FIRM, Encourages Emergent BioSolutions Inc. Investors with Losses to Secure Counsel Before Important Deadline – EBS - Business Wire
Emergent BioSolutions sets $50 million stock buyback plan By Investing.com - Investing.com South Africa
Emergent BioSolutions Authorizes $50 Million Stock Buyback Program - MarketScreener
Emergent BioSolutions Announces Repurchase Of Up To $50 Mln Stock, Pre-market Stock Up - Nasdaq
Emergent BioSolutions sets $50 million stock buyback plan - Investing.com
$50M Stock Buyback: Emergent BioSolutions Signals Strong Confidence in Turnaround Plan - Stock Titan
Q1 Earnings Estimate for EBS Issued By HC Wainwright - MarketBeat
Emergent BioSolutions: I See Further Downside Ahead In This Value Trap (NYSE:EBS) - Seeking Alpha
SEC Form DEFA14A filed by Emergent BioSolutions Inc. - Quantisnow
Expert Outlook: Emergent BioSolutions Through The Eyes Of 5 Analysts - Benzinga
Benign Growth For Emergent BioSolutions Inc. (NYSE:EBS) Underpins Stock's 31% Plummet - simplywall.st
Emergent BioSolutions New Hire Equity Grant Under NYSE Rule 303A.08 - The Manila Times
Just Awarded: Emergent BioSolutions Grants Major 72,882 Share Package to Strategic New Hire - Stock Titan
Emergent BioSolutions: Attractive Biotech With Proven Business Clouded By Washington Funding Issues - Seeking Alpha
Hikma announces Health Canada approval of KLOXXADO® (naloxone HCl) Nasal Spray 8 mg - The Manila Times
Breakthrough: New High-Dose Naloxone Spray Gets Health Canada Green Light as Overdose Crisis Persists - StockTitan
Syngene concludes acquisition of biologics manufacturing facility from Emergent BioSolutions - Medical Dialogues
Emergent BioSolutions Finalizes Sale of Baltimore-Bayview Manufacturing Site to Syngene International - citybiz
Syngene concludes the acquisition of Biologics Manufacturing Facility from Emergent BioSolutions Inc. - equitybulls.com
Emergent BioSolutions sells Baltimore facility to Syngene By Investing.com - Investing.com South Africa
Emergent BioSolutions Completes Sale of Baltimore-Bayview Facility to Syngene International - Marketscreener.com
Emergent BioSolutions sells Baltimore facility to Syngene - Investing.com India
Emergent Biosolutions finalizes sale of Baltimore-Bayview manufacturing site to Syngene International - Marketscreener.com
Emergent BioSolutions Strategic Win: $36.5M Facility Sale While Securing Future Production Rights - StockTitan
Emergent BioSolutions secures $27 million in MCM orders By Investing.com - Investing.com Australia
Emergent BioSolutions secures $27 million in MCM orders - Investing.com
Emergent BioSolutions Announces Approximately $27 Million in Incremental Sales to Supply International Customers with Five Critical Medical Countermeasure Products - The Manila Times
Emergent BioSolutions Announces Approximately $27 Million in Incremental Sales to Supply International - EIN News
Syngene Acquires First US Manufacturing Facility - Contract Pharma
Emergent BioSolutions Expands Global Reach with $27M Medical Defense Deal - Stock Titan
India-based Syngene acquires its first US biologics site - Manufacturing Dive
Emergent Biosolutions Inc (EBS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.77%
0.87%
자본화:
|
볼륨(24시간):